ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.

NCT00077636 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

1469

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C, Chronic

Interventions

DRUG: Copegus
DRUG: Copegus
DRUG: peginterferon alfa-2a [Pegasys]
DRUG: peginterferon alfa-2a [Pegasys]

Sponsor

Hoffmann-La Roche